Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial | BMC Cancer User montaukwhaler, in the non small cell lung cancer subreddit, 02 Jul 2021